Seroatlas · Human Serome Atlas

GREM2

Gremlin-2

Also known as: CKTSF1B2, DAND3, FLJ21195, GREM2_HUMAN, Prdc

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9H772
Gene
GREM2
Ensembl
ENSG00000180875
Chromosome
1
Canonical length
168 aa
Protein class
Disease related genes, Human disease related genes, Predicted secreted proteins
Secretome location
Secreted to blood
Quaternary structure
Homodimer

OverviewNCBI Gene

This gene encodes a member of the BMP (bone morphogenic protein) antagonist family. Like BMPs, BMP antagonists contain cystine knots and typically form homo- and heterodimers. The CAN (cerberus and dan) subfamily of BMP antagonists, to which this gene belongs, is characterized by a C-terminal cystine knot with an eight-membered ring. The antagonistic effect of the secreted glycosylated protein encoded by this gene is likely due to its direct binding to BMP proteins. As an antagonist of BMP, this gene may play a role in regulating organogenesis, body patterning, and tissue differentiation. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

168 residues, UniProt reviewed canonical sequence.

>Q9H772|GREM2
     1  MFWKLSLSLF LVAVLVKVAE ARKNRPAGAI PSPYKDGSSN NSERWQHQIK EVLASSQEAL
    61  VVTERKYLKS DWCKTQPLRQ TVSEEGCRSR TILNRFCYGQ CNSFYIPRHV KKEEESFQSC
   121  AFCKPQRVTS VLVELECPGL DPPFRLKKIQ KVKQCRCMSV NLSDSDKQ

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against GREM2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Secreted
Secreted
Yes
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.48
Highest tissue expression
29 nTPM

Expression across tissuesHPA

Tissue

  • gallbladder: 29 nTPM
  • liver: 25 nTPM
  • parathyroid gland: 22 nTPM
  • rectum: 19 nTPM
  • esophagus: 16 nTPM
  • colon: 16 nTPM

Single-cell type

  • syncytiotrophoblasts: 886 nCPM
  • breast lactating cells: 565 nCPM
  • thymic myoid cells: 214 nCPM
  • somatotrophs: 213 nCPM
  • salivary acinar cells: 173 nCPM
  • retinal bipolar cells: 104 nCPM

Immune cell

  • memory CD4 T-cell: 0.5 nTPM
  • MAIT T-cell: 0.4 nTPM
  • memory CD8 T-cell: 0.2 nTPM
  • naive CD4 T-cell: 0.1 nTPM
  • neutrophil: 0.1 nTPM
  • basophil: 0 nTPM

Brain region

  • cerebral cortex: 20 nTPM
  • basal ganglia: 11 nTPM
  • thalamus: 11 nTPM
  • medulla oblongata: 9.7 nTPM
  • hypothalamus: 9.6 nTPM
  • white matter: 9.6 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about GREM2.

Disease | AllUniProt

Conditions GREM2 is implicated in, by any mechanism.

Disease | GeneticClinVar

1 pathogenic / likely-pathogenic of 25 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.27
gnomAD pLI
0.03
gnomAD missense Z
1.23
DepMap mean gene effect
0.08
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of GREM2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads GREM2 as an antibody target. Whether an autoantibody or antibody against GREM2 could matter depends on whether native GREM2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

GREM2 is annotated as secreted, so native GREM2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label GREM2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/GREM2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...